I think they would be even better off buying another Sofdra opportunity. that's only taken 2 years to get approved and now revenue about to start.
acne and others still needs phase 3 trials which is more risky and costly than just buying something ready for a final NDA submission that another company can't afford to do or doesn't have the personal.
We can offer that to these smaller biotechs now and more nimble than big pharmas.
There are a lot of these opportunities out there.
I think they would be even better off buying another Sofdra...
-
- There are more pages in this discussion • 255 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |